(Q24234036)

3

0 references

Suetonia Palmer

2

0 references

Jonathan Craig

4

Jonathan C Craig

0 references

Giovanni Strippoli

6

Giovanni FM Strippoli

0 references

Sankar Navaneethan

1

Sankar D Navaneethan

0 references

Grahame Elder

5

Cochrane Database of Systematic Reviews

Grahame J Elder

0 references

publication date

16 February 2011

0 references

published in

0 references

cites work

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Comparison of Calcium Carbonate and Aluminium Hydroxide as Phosphate Binders on Biochemical Bone Markers, PTH(1-84), and Bone Mineral Content in Dialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Metabolic and skeletal effects of low and high doses of calcium acetate in patients with preterminal chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Phosphate-binding effects of sucralfate in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Pathogenesis of vascular calcification in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Hyperphosphatemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

21 January 2018

Oral phosphate binders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Annual progression of coronary calcification in trials of preventive therapies: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Interventions for preventing bone disease in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A new era in phosphate binder therapy: what are the options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

The details bedevil DCOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Hypothesis versus association: the optimal hemoglobin target debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Sunset for statins after AURORA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Calcium-based phosphate binders are appropriate in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Economic evaluation of sevelamer in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

An economic evaluation of sevelamer in patients new to dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Haemoglobin targets: we were wrong, time to move on

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

Calcium acetate control of serum phosphorus in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

The Treatment of Uraemic Hyperphosphataemia with Calcium Acetate and Calcium Carbonate: A Comparative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

The case against calcium-based phosphate binders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Phosphate binders: hold the calcium?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Cellular and molecular mechanisms of secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006023.PUB2

7 January 2021